What is IDYA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.48B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IDYA?

P/E (TTM) is n/a and 52-week range is $26.05 to $42.68 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IDYA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IDYA?

The company profile lists revenue (TTM) near $242M, net income (TTM) near $-18.08B, EPS (TTM) near $-1.94 when available from the market-data feed. Figures are informational and may lag live markets.

Where is IDEAYA Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 95.1M shares outstanding, ISIN US45166A1025 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

IDEAYA Biosciences Inc

$IDYA

Health Care · Biotechnology

IR Run Scenarios

$36.11

+0.14%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 145 full-time employees. The company went IPO on 2019-05-23. The firm is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.

Employees

145

Website

www.ideayabio.com/

IPO

2019-05-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)